Dr Anthony Williams joins Neotropix
This article was originally published in Scrip
Neotropix, a US clinical-stage development company focused in neuroendocrine cancer treatments, has named Dr Anthony Williams chief medical officer. Dr Williams has more than 25 years' drug development experience, having previously served as vice-president of medical research at Synta Pharmaceuticals. He has also worked at GlaxoSmithKline, Merrell Dow and Dyax.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.